Recent Updates — XFOR

X4 Pharmaceuticals entered into a Loan and Security Agreement with K2 HealthVentures for a senior secured term loan facility totaling up to $150 million. The first tranche, amounting to $80 million, was funded on October 7, 2026, and used to repay the outstanding obligations under the prior Hercules Loan Agreement, which had approximately $75 million in principal plus fees. An additional $70 million remains available at the company's request, subject to lender approval. The facility carries a variable interest rate with an initial interest-only period through October 1, 2029, and matures on October 1, 2030. It includes a conversion option allowing lenders to convert up to $15 million of principal into common stock at $3.2341 per share. X4 Pharmaceuticals is a biotechnology company developing therapies for rare hematology diseases.

On September 8, 2026, X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the U.S. Food and Drug Administration regarding the global 4WARD Phase 3 clinical trial for mavorixafor. The FDA agreed to reduce the required sample size from 176 to 126 participants while maintaining adequate statistical power for co-primary endpoints: reduction in annualized infection rate and positive absolute neutrophil count response. Management expects enrollment completion by year-end 2026 and topline data release in the first half of 2028. X4 Pharmaceuticals is a biotechnology company focused on developing therapies for rare hematology diseases.

X4 Pharmaceuticals, Inc. appointed Kelly Gold as a Class II director and Audit Committee member, effective July 1, 2026. This appointment increased the Board of Directors from five to six members. X4 Pharmaceuticals, Inc. is a biopharmaceutical company.